Sage Therapeutics, Inc.
SAGE
$7.86
-$0.16-2.00%
| Weiss Ratings | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.45 | |||
| Price History | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 4.80% | |||
| 30-Day Total Return | 8.26% | |||
| 60-Day Total Return | 49.15% | |||
| 90-Day Total Return | 35.28% | |||
| Year to Date Total Return | 35.99% | |||
| 1-Year Total Return | -59.42% | |||
| 2-Year Total Return | -82.13% | |||
| 3-Year Total Return | -77.34% | |||
| 5-Year Total Return | -71.93% | |||
| 52-Week High % Change | -60.53% | |||
| 52-Week Low % Change | 73.59% | |||
| Price | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $20.32 | |||
| 52-Week Low Price | $4.62 | |||
| 52-Week Low Price (Date) | Nov 20, 2024 | |||
| 52-Week High Price (Date) | Mar 22, 2024 | |||
| Valuation | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 493.08M | |||
| Enterprise Value | 495.19K | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -6.60 | |||
| Earnings Per Share Growth | -27.13% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 11.91 | |||
| Price/Book (Q) | 1.06 | |||
| Enterprise Value/Revenue (TTM) | 0.01 | |||
| Price | $7.86 | |||
| Enterprise Value/EBITDA (TTM) | 0.00 | |||
| Enterprise Value/EBIT | 0.00 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 61.26M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 299 8380 | |||
| Address | 55 Cambridge Parkway Cambridge, MA 02142 | |||
| Website | www.sagerx.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -995.36% | |||
| Profit Margin | -971.47% | |||
| Management Effectiveness | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -35.90% | |||
| Return on Equity | -- | |||
| Income Statement | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 41.24M | |||
| Total Revenue (TTM) | 41.24M | |||
| Revenue Per Share | $0.67 | |||
| Gross Profit (TTM) | -205.18M | |||
| EBITDA (TTM) | -409.49M | |||
| EBIT (TTM) | -410.52M | |||
| Net Income (TTM) | -400.67M | |||
| Net Income Avl. to Common (TTM) | -400.67M | |||
| Total Revenue Growth (Q YOY) | -83.56% | |||
| Earnings Growth (Q YOY) | -192.85% | |||
| EPS Diluted (TTM) | -6.60 | |||
| EPS Diluted Growth (Q YOY) | -186.76% | |||
| Balance Sheet | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 504.42M | |||
| Cash Per Share (Q) | $8.23 | |||
| Total Current Assets (Q) | 531.30M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 465.09M | |||
| Current Ratio (Q) | 7.419 | |||
| Book Value Per Share (Q) | $7.58 | |||
| Total Assets (Q) | 547.22M | |||
| Total Current Liabilities (Q) | 71.62M | |||
| Total Debt (Q) | 11.84M | |||
| Total Liabilities (Q) | 82.13M | |||
| Total Common Equity (Q) | 465.09M | |||
| Cash Flow | SAGE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 266.68M | |||
| Cash from Financing (TTM) | 10.66M | |||
| Net Change in Cash (TTM) | 10.15M | |||
| Levered Free Cash Flow (TTM) | -119.04M | |||
| Cash from Operations (TTM) | -267.19M | |||
